🟢 AIM ImmunoTech Inc is trading 33.3% up today after announcing early completion of enrollment for its Phase 2 pancreatic cancer trial

AIM ImmunoTech Inc is trading at $0.54 (33.3% up) after announcing a significant milestone in its pancreatic cancer program.

• The company announced it has completed enrollment of the final subject for its Phase 2 DURIPANC clinical trial ahead of its original July 2026 target. [6, 7]
• This milestone keeps the company on track for a planned December 2026 evaluation of the study's primary endpoint, the Clinical Benefit Rate. [7]
• Separately, Ascendiant Capital maintained a "Buy" rating on the stock on the same day, though it lowered its price target to $9.00 from $10.00. [8]